You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company is developing an RNA sequencing kit based on a technology that enables barcoding in a test tube format to prepare samples for single-cell profiling.
The company is developing a platform that is designed to provide an overview of an individual's health based on sequenced genetic data and other metrics.
The Series B round, which includes new and existing investors, follows the Belgian firm's completion of a €7.7 million private placement in 2016.
The firm, cofounded by several Harvard University researchers, is commercializing a single-cell spatial transcriptomics technology called MERFISH.
The University of Utah spinout said it will use the funding to enhance and expand its NGS-based Explify microbe identification platform and support its lab.
The firm has opened a $10 million Series A financing round that it expects to close in late summer to support running clinical studies for its assay.
The Beverly, Massachusetts-based company plans to use the funding to expand its PlexWell sequencing library prep technology into new areas.
The firm said it will use the funds to advance development of its HostDx immune response gene expression tests for acute infections and sepsis.
The Church Lab spinout has now raised more than $50 million to develop and commercialize its fluorescent in situ sequencing technology for spatial genomics.
The San Diego-based company plans to develop a flexible, modular, and high-performing sequencing platform based on proprietary technologies in different areas.
Researchers have developed a robotic lab assistant, the Verge reports.
CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.
The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.
In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.